| Market Cap | 3.57M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -8.09M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -6.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -78.00% |
| Dividend | N/A | Price/Book | 0.98 | EPS next 5Y | - | 52W High Chg | -92.00% |
| Recommedations | - | Quick Ratio | 1.90 | Shares Outstanding | 3.26M | 52W Low Chg | 28.00% |
| Insider Own | - | ROA | -49.59% | Shares Float | 3.21M | Beta | -1.69 |
| Inst Own | - | ROE | -181.83% | Shares Shorted/Prior | 160.15K/92.70K | Price | 0.47 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 487,282 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 181,129 | Change | 6.82% |
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
